Merrimack Pharmaceuticals, Inc. MACK
15.15 0.00 (+0.00%)
May 17, 2024, 3:59 PM EDT
15.14 Day range 15.17
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (0m) 3 0 buy · 3 hold · 0 sell
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -1.08 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -1.33 | 0.0% | 0 | 0.0% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2018 | Baird | Maintained | Neutral | Neutral |
| Jun 25, 2018 | Baird | Maintained | Neutral | Neutral |
| Jun 24, 2018 | JP Morgan | Downgrade | Neutral | Underweight |
| Oct 6, 2016 | JP Morgan | Downgrade | Overweight | Neutral |
| Aug 18, 2016 | BTIG | Initiated | — | Neutral |
| Aug 4, 2016 | JP Morgan | Maintained | — | Overweight |
| May 25, 2016 | Baird | Initiated | — | Neutral |
| Oct 26, 2015 | Oppenheimer | Maintained | — | Outperform |
| May 12, 2015 | Guggenheim | Initiated | — | Buy |
| Apr 20, 2015 | Mizuho | Maintained | — | — |
| Sep 8, 2014 | Cantor Fitzgerald | Initiated | — | Buy |
| Jun 19, 2014 | JP Morgan | Maintained | — | Overweight |
| Apr 30, 2014 | Cowen & Co. | Upgrade | — | Outperform |
| Aug 8, 2013 | B of A Securities | Downgrade | Buy | Neutral |
| Aug 7, 2013 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Jun 24, 2013 | Mizuho | Initiated | — | Buy |
| Sep 26, 2012 | Brean Capital | Initiated | — | Buy |
| Aug 30, 2012 | B of A Securities | Initiated | — | Buy |